p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy

Journal of Pathology

Volumn 191, Issue 1, 2000, Pages 33-38

  Warnakulasuriya, Saman ^a   Jia, Chaoying ^a   Johnson, Newell ^a   Houghton, Joan ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Head and neck cancer; Immunohistochemistry; P glycoprotein; p53; Prognosis

Indexed keywords

BLEOMYCIN; FLUOROURACIL; GLYCOPROTEIN P; METHOTREXATE; PROTEIN P53; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034012285     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200005)191:1<33::AID-PATH585>3.0.CO;2-B     Document Type: Article

References (59)

1. Edwards D, Johnson NW. Chemotherapy and survival of patients with head and neck cancers in England. Clin Oncol (in press).
2. Pignon JP, Bourhis J, Domenge C, Designe L, Armand JP, Luboinski B. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC) loco-regional treatment versus same treatment+chemotherapy. In Eurocancer 98, Biron M, Marty M (eds). John Libby: Paris, 1998; 15-16.
3. Lowe SW, Ruley EH, Jacks T, Housman DE. p53 dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 1993; 74: 957-967.
4. Fisher DE. Apoptosis in cancer therapy: crossing the threshold (mini review). Cell 1995; 78: 539-542.
5. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999; 187: 127-137.
6. Lane DP. The regulation of p53 function: Steiner Award Lecture. Int J Cancer 1994; 57: 623-627.
7. Benhattar J, Cerottini JP, Saraga E. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996; 69: 190-192.
8. Hamada M, Fujiwara T, Hizuta A. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996; 122: 360-365.
9. Brett MC, Pickard M, Green B. p53 protein overexpression and response to biomodulatcd 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 1996; 22: 182-185.
10. Rusch V, Klimstra D, Venkatraman E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995; 55: 5038-5042
11. Bergh J, Norberg T, Sjögren S. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1995; 1: 1029-1034.
12. Aas T, Børresen A-L, Geisler S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811-813.
13. Eid R, Van der Looij M, Institoris E, et al. Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer? Anticancer Res 1997; 17: 2663-2669.
14. Linn SC, Honkoop AH, Hoekman K. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996; 74: 63-68.
15. Kirsch DG, Kastan MB. Tumour-suppressor p53: implications for tumour development and prognosis. J Clin Oncol 1998; 16: 3158-3168.
16. Waldman T, Lengaucr C, Kinzler C, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381: 713-716.
17. Cote RJ, Esrig D, Groshen S, et al. p53 and treatment of bladder cancer. Nature 1997; 385: 123-125.
18. Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998; 77: 621-626.
19. Puglisi F, Di-Loreto C, Panizzo R, et al. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. J Clin Pathol 1996; 49: 456-459.
20. Gasparini G, Bevellacque P, Bonoldi E, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1995; 1: 1375-1383.
21. Wilson GD, Richman PI, Dische S, et al. p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. Br J Cancer 1995; 71: 1248-1252.
22. Riva C, Lavieille JP, Reyt E, Brambilla B, Lunardi J, Brambilla C. Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of head and neck: implication in drug and radioresistance. Eur J Cancer 1995; 31B: 384-391.
23. Dunphy CR, Dunphy FR, Boyd JH, et al. Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy. Arch Otolaryngol Head Neck Surg 1997; 123: 1223-1235.
24. Hegde PV, Brenski AC, Caldarelli DD, et al. Tumour angiogenesis and p53 mutations: prognosis in head and neck cancer. Arch Otolaryngol Head Neck Surg 1998; 124: 80-85.
25. Bradford CR, Zhu S, Poore J, et al. p53 mutations as a prognostic marker in advanced laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 1997; 123: 605-609.
26. Tan LKS, Ogden GP. p53 expression in laryngeal carcinoma is not predictive of response to radiotherapy. Eur J Cancer Oral Oncol 1997; 33B: 177-181.
27. Chiang CP, Huang JS, Wang JT, et al. Expression of p53 protein correlates with decreased survival in patients with areca quid chewing and smoking-associated oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 1999; 28: 72-76.
28. Trambas CM, Muller HK, Woods GM. P-glycoprotein mediated multidrug resistance and its implications for pathology. Pathology 1997; 29: 122-130.
29. Sugawara I. Multidrug resistance: role of multidrug resistance-associated protein (MRP). Cancer J 1995; 8: 59-61.
30. Mechetner E, Kyshtoobayeva A, Zonis S, et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998; 4: 389-398.
31. Punyammalee B, Manoromana S, Purisa W, Chariyalertsak S, Rerkamnuaycbok B. Association of mdrl gene expression with other prognostic factors and clinical outcome in human breast cancer. J Med Assoc Thai 1997; 80 1997; 80 (Suppl 1): S162-S173.
32. Punyammalee B, Manoromana S, Purisa W, Chariyalertsak S, Rerkamnuaycbok B. Association of mdrl gene expression with other prognostic factors and clinical outcome in human breast cancer. J Med Assoc Thai 1997; 80 1997; 80 (Suppl 1): S162-S173.
33. Chou YY, Cheng AL, Hsu HC. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol 1997; 12: 569-575.
34. Khalifa MA, Abdoh AA, Mannel RS, Walker JL, Angros LH, Min KW. P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma. Int J Gynecol Pathol 1997; 16: 69-75.
35. Bodey B, Bodey B Jr, Groger AM, et al. Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumour suppressor gene proteins in human breast cancer cells: clinical and therapeutical significance. Anticancer Res 1997; 17: 1311-1318.
36. SECOG. A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. Eur J Surg Oncol 1986; 12: 289-295.
37. Warnakulasuriya KAAS, Johnson NW. Expression of p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions. J Oral Pathol Med 1992; 21: 404-408.
38. Tobias JS. Management of head and neck cancer in Britain. Br Med J 1997; 315: 1556.
39. Berrino F, Sant M, Capocaccia R, Hakulinen T, Esteve J. Survival of cancer patients in Europe: the EUROCARE study. IARC (Int Agency Res Cancer) Sci Publ 1995; No. 132.
40. Edwards D, Johnson NW, Cooper D, Warnakulasuriya KAAS. Management of cancers of the head and neck in the United Kingdom: questionnaire survey of consultants. Br Med J 1997; 315: 1589.
41. Gamel JW, Jones AS. Squamous carcinoma of the head and neck: cured fraction and median survival time as functions of age, sex, histologic type, and node status. Br J Cancer 1993; 67: 1071-1075.
42. Jones AS, Hanafi ZB, Nadapalan V, Roland NJ, Kinsella A, Helliwell TR. Do positive margins after ablative surgery for head and neck cancer adversely affect prognosis? A study of 352 patients with recurrent carcinoma following radiotherapy treated by salvage surgery. Br J Cancer 1996; 74: 128-132.
43. Janot F, Klijanienko J, Russo A, et al. Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer 1996; 73: 531-538.
44. Faye-Lund H, Abdelnoor M. Prognostic factors of survival in a cohort of head and neck cancer patients in Oslo. Eur J Cancer Oral Oncol 1996; 32B: 83-90.
45. Jones AS. Prognosis in mouth cancer: tumour factors. Eur J Cancer Oral Oncol 1994; 30B: 8-15.
46. Edwards D, Johnson NW. Treatment of upper aerodigestive tract cancers in England and its effect on survival. Br J Cancer 1999; 81: 323-329.
47. American Society for Clinical Oncology. 1997 update of recommendations for the use of tumour markers in breast and colorectal cancer. J Clin Oncol 1998; 16: 793-795.
48. Dowell SP, Hall PA. The p53 tumour suppressor gene and tumour prognosis: is there a relationship? J Pathol 1995; 177: 221-224.
49. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 1999; 187: 8-18.
50. Slootweg PJ. Suppressor protein p53 and its occurrence in oral tumours. In Current Topics in Pathology, Seifert G (ed.). Springer-Verlag: Berlin, 1996; 180-200.
51. Field JK, Pavelic ZP, Spandidos DA, et al. The role of p53 tumour suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck 1993; 119: 1118-1122.
52. Warnakulasuriya KAAS, Johnson NW. p53 overexpression in oral carcinoma: divergence in different populations and some caveats in immunohistochemistry. In Head and Neck Cancer: Advances in Basic Research, Werner JA, Lippert BM, Rudert HH (eds). Elsevier: Amsterdam, 1996; 307-311.
53. Pavelic ZP, Reising J, Pavelic L, et al. Detection of P-glycoprotein with four monoclonal antibodies in normal and tumour tissues. Arch Otolaryngol Head Neck 1993; 119: 753-757.
54. Chan HSL, Ling V, Anti-P-glycoprotein antibody C219 cross-reactivity with c-erbB2 protein: diagnostic and clinical implications. J Natl Cancer Inst 1997; 89: 1473-1477.
55. Gala JL, McLachlan JM, Bell DR, Michaux JL, Ma DDF. Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies. J Clin Pathol 1994; 47: 619-624.
56. Ohshima T, Sugawara I, Fugita H. Relationship of p53 tumour suppressor gene product and expression of the multidrug resistance gene (MDR-1). 4th International Conference of Oral Cancer. Gifu, Japan, 1995.
57. Erber R, Conradt C, Homann N, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998; 16: 1671-1679.
58. Berns EMJJ, van Staveren IL, Look MP, Smid M, Klijn JGM, Foekens JA. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 1998; 77: 1130-1136.
59. Pirollo KF, Hao Z, Rait A, et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997; 14: 1735-1746.